Abstract
Encainide is a new agent for treating ventricular arrhythmias. We attempted long-term oral therapy with encainide in 38 patients with recurrent, strikingly drug-refractory ventricular tachycardia. The usual daily dose of encainide ws 150-250 mg divided into four or six doses. The mean period until withdrawal of encainide or the date of follow-up was 4.2 months. Encainide completely eliminated recurrence of ventricular tachycardia in 54% of the patients for 6 months of therapy and in 29% of the patients for 18-30 months of therapy. Twelve patients (32%) had side effects possibly due to encainide; in four, the arrhythmia may have been worsened by encainide. During chronic therapy, encainide increased the PR interval by 18% and the QRS duration by 32%. There was no significant change in the corrected QT interval. The presence of QRS prolongation appeared to correlate with antiarrhythmic effect. We conclude that encainide is a safe, well-tolerated antiarrhythmic agent that is often effective against previously drug-refractory ventricular tachycardia.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference9 articles.
1. Gibson JK Somani P Bassett AL: Effect of MJ 9067 on transmembrane potentials of canine cardiac Purkinje fibers. (abstr) Pharmacologist 18: 169 1976
2. Canine electrophysiology of encainide, a new antiarrhythmic drug
3. Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent
4. Vaughan Williams EM: Classification of antiarrhythmic drugs. In Symposium on Cardiac Arrhythmias edited by Sand 0e E Flensted-Jensen E Olesen KH. Sweden Astra 1970 p 449
5. Spitz AL Fitzgerald JW Harrison DC: Ambulatory arrhythmia quantification by a correlation technique. In Computers in Cardiology Rotterdam 1977 p 225
Cited by
98 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献